Welcome to the Podiatry Arena forums

You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members, upload content, view attachments, receive a weekly email update of new discussions, access other special features. Registered users do not get displayed the advertisements in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!

  1. Have you considered the Clinical Biomechanics Boot Camp Online, for taking it to the next level? See here for more.
    Dismiss Notice
Dismiss Notice
Have you considered the Clinical Biomechanics Boot Camp Online, for taking it to the next level? See here for more.
Dismiss Notice
Have you liked us on Facebook to get our updates? Please do. Click here for our Facebook page.
Dismiss Notice
Do you get the weekly newsletter that Podiatry Arena sends out to update everybody? If not, click here to organise this.

Basal Cell Carcinoma

Discussion in 'General Issues and Discussion Forum' started by NewsBot, Sep 17, 2016.

Tags:
  1. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1

    Members do not see these Ads. Sign Up.
    Basal Cell Carcinoma of the Dorsal Foot: An Update and Comprehensive Review of the Literature.
    Loh TY, Rubin AG, Jiang SI.
    Dermatol Surg. 2016 Sep 14
     
  2. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Basal Cell Carcinoma on the Sole: An Easily Missed Cancer.
    Hone NL et al
    Case Rep Dermatol. 2016 Oct 13;8(3):283-286.
     
  3. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    PUBLIC RELEASE: 13-DEC-2016
    Topical skin cream for treatment of basal cell carcinoma shows promise as an alternative to surgery
    Initial treatment success with imiquimod appears to be sustained over a 5-year period, reports the Journal of Investigative Dermatology
     
  4. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Press Release:
    Why Basal Cell Tumors Return When Drug Treatment Stops
    Researchers uncover a mechanism that explains why a Hedgehog inhibitor kills skin cancer, but not completely.


    What happens when the most common and least threatening type of cancer gets complicated?

    A new study pinpoints a mechanism that controls how basal cell cancers respond to treatment and offers new ideas for controlling this disease when it gets tricky.

    Basal cell carcinomas are incredibly common — between 1 million and 3 million Americans are diagnosed each year — and rarely life-threatening. They are most often removed through surgery.

    But for a small minority of patients, they can be a bigger problem.

    In some cases, the cancer cannot be surgically removed, often because of where it’s found. A small portion of patients have an inherited condition called basal cell nevus syndrome, or Gorlin syndrome, which causes hundreds of basal cell tumors to develop over their lifetimes.

    Enter the drug vismodegib. It’s an early success story among targeted therapies, developed to hit a key pathway in basal cell carcinoma called Hedgehog. By blocking Hedgehog, the cancer cells die.

    But there’s one catch: When patients stop taking the drug, the cancer often grows back at the same site.

    “It’s a very effective drug, but many patients have to stay on it for their entire life,” says Sunny Wong, Ph.D., assistant professor of dermatology and of cell and development biology at Michigan Medicine. “We think vismodegib drives a subset of tumor cells into a state of dormancy, where they neither grow nor die.”

    In a study in Cancer Cell, researchers describe two types of cell populations in basal cell tumors. The outer edge of the tumor is lined with cells that persist even in the face of Hedgehog blockade. The inner cells, on the other hand, are about three times more likely to undergo cell death from vismodegib treatment.

    “What was most fascinating was that the relative location of a cell within a tumor can have such a big effect on its sensitivity to drug treatment,” says lead study author Markus Eberl, Ph.D., a former postdoctoral fellow at Michigan Medicine.

    The difference stems from the Notch pathway and how each type of cell activates it. Higher levels of Notch were detected in the inner cells, while the outer cells had lower levels. When the researchers shut off Notch, tumors were more likely to persist despite vismodegib treatment. When they turned on Notch, tumors shrank. The work was done in mice.

    The outer cells are anchored to the tumor’s basement membrane, where Hedgehog signaling is high and Notch signaling is low. The researchers explain that this pattern allows cancer cells to persist in a largely dormant state while the patient takes the Hedgehog-inhibiting vismodegib. Once the drug treatment stops, the dormant cells reactivate.

    Notch plays a key role in normal skin and is the most common mutation in skin cancers, seen in up to half of patients.

    Fewer than 1 percent of patients with basal cell tumors will need vismodegib.

    “The side effects of vismodegib are not life-threatening, but there are concerns,” Wong notes.

    Many patients experience loss of taste, muscle cramps, weight loss and fatigue. The side effects drive some patients to discontinue the drug.

    Drug resistance and tumor persistence are both challenging issues with Hedgehog-blocking treatments. This is the first study to address persistence and explain how the drug works and, in some cases, falls short.

    “Eliminating persistent tumor cells is necessary to cure patients who have tough-to-treat cases of basal cell carcinoma,” Eberl says.

    The researchers suggest the key might be in developing a drug that changes the tumor architecture so the persistent outer cells respond more like the inner cells. Additional research is underway into the mechanisms of why Notch affects cell death, searching for proteins or molecules that may be at play.
     
  5. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Ulcerated Basal Cell Carcinomas Masquerading as Venous Leg Ulcers.
    Tchanque-Fossuo CN1, Millsop JW, Johnson MA, Dahle SE, Isseroff RR.
    Adv Skin Wound Care. 2018 Mar;31(3):130-134. doi: 10.1097/01.ASW.0000530068.44631.dc.
     
  6. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    BASAL CELL CARCINOMA OF THE FOOT - TWO CASE REPORTS AND LITERATURE REVIEW.
    Wollina U, Schönlebe J, Langner D
    Georgian Med News. 2018 Mar;(276):55-59.
     
Loading...

Share This Page